CL2013003567A1 - Anhydrous crystalline form of {(s) -3- [6- (6-methoxy-5-methyl-pyridin-3-yl) -5,6,7,8-tetrahydro-pyrido [4,3-d] pyrimidin- 4-yloxy] -pyrrolidin-1-yl} - (tetrahydro-pyran-4-yl) -methanone, salts thereof; pharmaceutical composition; pharmaceutical combination; use in the treatment of autoimmune, inflammatory, allergic disorders, transplant rejection, among others. - Google Patents

Anhydrous crystalline form of {(s) -3- [6- (6-methoxy-5-methyl-pyridin-3-yl) -5,6,7,8-tetrahydro-pyrido [4,3-d] pyrimidin- 4-yloxy] -pyrrolidin-1-yl} - (tetrahydro-pyran-4-yl) -methanone, salts thereof; pharmaceutical composition; pharmaceutical combination; use in the treatment of autoimmune, inflammatory, allergic disorders, transplant rejection, among others.

Info

Publication number
CL2013003567A1
CL2013003567A1 CL2013003567A CL2013003567A CL2013003567A1 CL 2013003567 A1 CL2013003567 A1 CL 2013003567A1 CL 2013003567 A CL2013003567 A CL 2013003567A CL 2013003567 A CL2013003567 A CL 2013003567A CL 2013003567 A1 CL2013003567 A1 CL 2013003567A1
Authority
CL
Chile
Prior art keywords
tetrahydro
methanone
pyrido
yloxy
pyrrolidin
Prior art date
Application number
CL2013003567A
Other languages
Spanish (es)
Inventor
Klemens Hogenauer
Gregory HOLLINGWORTH
Nicolas Soldermann
Frank Stowasser
Nicolas Tufilli
Frederic Zecri
Gomes Dos Santos Paulo Antonio Fernandes
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2013003567A1 publication Critical patent/CL2013003567A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2013003567A 2011-06-27 2013-12-12 Anhydrous crystalline form of {(s) -3- [6- (6-methoxy-5-methyl-pyridin-3-yl) -5,6,7,8-tetrahydro-pyrido [4,3-d] pyrimidin- 4-yloxy] -pyrrolidin-1-yl} - (tetrahydro-pyran-4-yl) -methanone, salts thereof; pharmaceutical composition; pharmaceutical combination; use in the treatment of autoimmune, inflammatory, allergic disorders, transplant rejection, among others. CL2013003567A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IR1390040156 2011-06-27

Publications (1)

Publication Number Publication Date
CL2013003567A1 true CL2013003567A1 (en) 2014-08-08

Family

ID=50231547

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013003567A CL2013003567A1 (en) 2011-06-27 2013-12-12 Anhydrous crystalline form of {(s) -3- [6- (6-methoxy-5-methyl-pyridin-3-yl) -5,6,7,8-tetrahydro-pyrido [4,3-d] pyrimidin- 4-yloxy] -pyrrolidin-1-yl} - (tetrahydro-pyran-4-yl) -methanone, salts thereof; pharmaceutical composition; pharmaceutical combination; use in the treatment of autoimmune, inflammatory, allergic disorders, transplant rejection, among others.

Country Status (14)

Country Link
EP (1) EP2723740A1 (en)
JP (1) JP2014518256A (en)
KR (1) KR20140025530A (en)
CN (1) CN103608349A (en)
AU (1) AU2012277391A1 (en)
CA (1) CA2840315A1 (en)
CL (1) CL2013003567A1 (en)
CO (1) CO6821957A2 (en)
EA (1) EA201490164A1 (en)
MA (1) MA35203B1 (en)
MX (1) MX2013015001A (en)
SG (1) SG195067A1 (en)
TN (1) TN2013000483A1 (en)
WO (1) WO2013001445A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3251673A1 (en) 2012-12-13 2017-12-06 IP Gesellschaft für Management mbH Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer
CN104945367A (en) * 2015-06-04 2015-09-30 聂超 Benzaldehyde propylene glycolacetal and preparation method thereof
AU2017204936B2 (en) * 2016-02-10 2019-06-27 Novartis Ag Use of inhibitors of the activity or function of PI3K for the treatment of primary Sjogren's Syndrome

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
ATE28864T1 (en) 1982-07-23 1987-08-15 Ici Plc AMIDE DERIVATIVES.
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US5010099A (en) 1989-08-11 1991-04-23 Harbor Branch Oceanographic Institution, Inc. Discodermolide compounds, compositions containing same and method of preparation and use
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
TW225528B (en) 1992-04-03 1994-06-21 Ciba Geigy Ag
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
DE69536015D1 (en) 1995-03-30 2009-12-10 Pfizer Prod Inc Quinazolinone derivatives
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
BR9609617B1 (en) 1995-07-06 2010-07-27 7h-pyrrol [2,3-d] pyrimidine derivatives, and pharmaceutical composition.
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
CA2249446C (en) 1996-04-12 2008-06-17 Warner-Lambert Company Irreversible inhibitors of tyrosine kinases
WO1997049688A1 (en) 1996-06-24 1997-12-31 Pfizer Inc. Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
JP2001500851A (en) 1996-08-30 2001-01-23 ノバルティス アクチエンゲゼルシャフト Process for producing epothilone and intermediate products obtained during the process
EP0938597B1 (en) 1996-09-06 2003-08-20 Obducat Aktiebolag Method for anisotropic etching of structures in conducting materials
CA2265630A1 (en) 1996-09-13 1998-03-19 Gerald Mcmahon Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
CN100344627C (en) 1996-11-18 2007-10-24 生物技术研究有限公司(Gbf) Epothilones C, and its preparation and use as cell inhibitor
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
CO4940418A1 (en) 1997-07-18 2000-07-24 Novartis Ag MODIFICATION OF A CRYSTAL OF A DERIVATIVE OF N-PHENYL-2-PIRIMIDINAMINE, PROCESSES FOR ITS MANUFACTURE AND USE
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
IL138113A0 (en) 1998-02-25 2001-10-31 Sloan Kettering Inst Cancer Synthesis of epothilones, intermediates thereto and analogues thereof
ES2342240T3 (en) 1998-08-11 2010-07-02 Novartis Ag ISOQUINOLINE DERIVATIVES WITH ACTIVITY INHIBITED BY ANGIOGENIA.
KR100716272B1 (en) 1998-11-20 2007-05-09 코산 바이오사이언시즈, 인코포레이티드 Recombinant methods and materials for producing epothilone and epothilone derivatives
PE20020354A1 (en) 2000-09-01 2002-06-12 Novartis Ag HYDROXAMATE COMPOUNDS AS HISTONE-DESACETILASE (HDA) INHIBITORS
NZ525656A (en) 2000-11-07 2004-12-24 Novartis Ag Indolylmaleimide derivatives as protein kinase C inhibitors
AR035885A1 (en) 2001-05-14 2004-07-21 Novartis Ag DERIVATIVES OF 4-AMINO-5-FENIL-7-CYCLLOBUTILPIRROLO (2,3-D) PYRIMIDINE, A PROCESS FOR ITS PREPARATION, A PHARMACEUTICAL COMPOSITION AND THE USE OF SUCH DERIVATIVES FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
TW200918046A (en) 2002-04-03 2009-05-01 Novartis Ag Indolylmaleimide derivatives
US7365096B2 (en) 2002-12-09 2008-04-29 Board Of Regents, The University Of Texas System Methods for selectively inhibiting Janus tyrosine kinase 3 (Jak3)
ZA200602666B (en) 2004-01-12 2007-09-26 Cytopia Res Pty Ltd Selective kinase inhibitors
ES2427999T3 (en) * 2007-04-17 2013-11-05 Evotec Ag 2-Cyanophenyl-condensed heterocyclic compounds and compositions and uses thereof
UA112517C2 (en) 2010-07-06 2016-09-26 Новартіс Аг TETRAHYDROPYRIDOPYRIMIDINE DERIVATIVES

Also Published As

Publication number Publication date
CN103608349A (en) 2014-02-26
MA35203B1 (en) 2014-06-02
AU2012277391A1 (en) 2013-12-19
KR20140025530A (en) 2014-03-04
EA201490164A1 (en) 2014-04-30
MX2013015001A (en) 2014-03-31
JP2014518256A (en) 2014-07-28
EP2723740A1 (en) 2014-04-30
WO2013001445A1 (en) 2013-01-03
TN2013000483A1 (en) 2015-03-30
CA2840315A1 (en) 2013-01-03
CO6821957A2 (en) 2013-12-31
SG195067A1 (en) 2013-12-30

Similar Documents

Publication Publication Date Title
IL257410A (en) Pyrazolo [1, 5 -a] pyrimidines as antiviral agents
SMT201600164B (en) NEW N-ACYL-5, 6, 7, (8-SODSTITUTED) -TETRAIDRO- [1, 2, 4] TRIAZOL [4, 3-A] CHIRAL PIRAZINES AS SELECTIVE ANTAGONISTS OF THE NK-3 RECEPTOR, PHARMACEUTICAL COMPOSITION, AND METHODS FOR USE IN DISORDERS MEDIATED BY NK-3 RECEPTOR
HK1218546A1 (en) Novel n-acyl-(3-substituted)-(8-methyl)-5,6-dihydro- [1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, methods for use in nk-3 receptor-mediated disorders nk-3 n--(3-)-(8-)-56-- [124][43-a] nk-3
CL2013002177A1 (en) Compounds derived from 9h-purines and 7h-pyrrolo [2,3-d] -pyrimidines substituted, inhibitors of pi3k class i and / or mtor; its pharmaceutical composition; its pharmaceutical combination; and its use in the treatment or prevention of cancer or neurodegenerative disorders.
IL235659A0 (en) Substituted 3, 4 - dihydro - 2h - pyrido [1, 2 - a] pyrazine - 1, 6 - dione derivatives useful for the treatment of (inter alia) alzheimer's disease
PT2794611T (en) Pyrazolo[1,5-a]pyrimidines as antiviral agents
SG11201402197UA (en) [1, 2, 3] triazolo [4, 5 -d] pyrimidine derivatives as agonists of the cannabinoid receptor 2
NZ626394A (en) Substituted annulated pyrimidines and triazines, and use thereof
DOP2011000291A (en) COMPOSITIONS OF PROPANE-1-SULPHONIC ACID {3- [5- (4-CHLORINE-PHENYL) -1H-PIRROLO [2,3-B] -PIRIDINA-3-CARBONIL] -2,4-DIFLUORO-PHENIL} -AMIDA AND THE USE OF THE SAME
IL234272B (en) N-(5s,6s,9r)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridin-9-yl-4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate, hemisulfate salt
CO6990726A2 (en) Pharmaceutical compositions of 7- (6- (2-hydroxypropan-2-yl) pyridin-3-yl) -1 - ((trans) -4-methoxycyclohexyl) -3,4-dihydropyrazine [2,3-ß] pyrazine- 1 (1h) -one, a solid form thereof and methods of use
CL2015002635A1 (en) Compounds and compositions for the treatment of parasitic diseases
CO6930360A2 (en) Derivatives of [1,2,3] triazolo [4,5-d] pyrimidine as preferred agonists of the cannabinoid receptor 2
WO2011085990A8 (en) Anti - infective pyrido (1,2 -a) pyrimidines
IL227526A0 (en) 6-cyclobutyl-1,5-dihydro-pyrazolo [3,4-d]pyrimidin-4-one derivatives their use as pde9a inhibitors
CL2014002048A1 (en) Compounds derived from 4- (benzoimidazol-2-yl) -thiazole and related aza derivatives; pharmaceutical composition; and use in the prevention and treatment of autoimmune, inflammatory, infectious diseases, among others.
IN2015DN03751A (en)
DOP2012000142A (en) NEW POLYMORPH FORMS OF {4,6-DIAMINO-2- [1- (2-FLUOROBENCIL) -1H-PIRAZOLO [3,4-B] PIRIDIN-3-IL] PIRIMIDIN-5-IL} CARBAMATO DE METTILO
CL2013003567A1 (en) Anhydrous crystalline form of {(s) -3- [6- (6-methoxy-5-methyl-pyridin-3-yl) -5,6,7,8-tetrahydro-pyrido [4,3-d] pyrimidin- 4-yloxy] -pyrrolidin-1-yl} - (tetrahydro-pyran-4-yl) -methanone, salts thereof; pharmaceutical composition; pharmaceutical combination; use in the treatment of autoimmune, inflammatory, allergic disorders, transplant rejection, among others.
CL2011000832A1 (en) Compounds derived from thieno [2,3-d] substituted pyrimidin-4-amine, adenosine a2a receptor antagonist; pharmaceutical composition; and its use to treat neurodegenerative or motor disorders, among other diseases.
BRPI0906985A2 (en) Pyrido [4,3-d] pyrimidinone derivatives as kinase inhibitors